Back to dashboard
CommercialCoverageMedium impact

Erythropoiesis-Stimulating Agents

Blue Cross & Blue Shield of Mississippi·MS · Nephrology, Oncology, Hematology +1 more·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply

Summary

BCBS Mississippi updated their Erythropoiesis-Stimulating Agents policy covering Aranesp, Epogen, Procrit, and Retacrit. The policy clarifies medical necessity criteria for treating anemia in chronic kidney disease, HIV patients on zidovudine, cancer patients on chemotherapy, and pre-surgical patients.

Action Required

Action needed
Immediately: Billing team must verify formulary coverage for each patient's specific benefit plan before prescribing Aranesp, Epogen, Procrit, or Retacrit as noted in policy. Ensure documentation supports medical necessity criteria for chronic kidney disease, HIV with zidovudine therapy, chemotherapy-induced anemia, or pre-surgical anemia indications.

Affected Billing Codes

Q5105
Q5106
N18.30
N18.31
N18.32
D64.81